Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

666 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses.
Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Bonovas S, et al. Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:43-47. doi: 10.1016/j.bpg.2018.05.005. Epub 2018 Jun 11. Best Pract Res Clin Gastroenterol. 2018. PMID: 30060938 Review.
Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.
Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Aliment Pharmacol Ther. 2008 Oct 15;28(8):966-72. doi: 10.1111/j.1365-2036.2008.03811.x. Epub 2008 Jul 24. Aliment Pharmacol Ther. 2008. PMID: 18652603 Clinical Trial.
A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Roblin X, et al. Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Am J Gastroenterol. 2008. PMID: 19086961 Retracted. Clinical Trial.
666 results
Jump to page
Feedback